ScholarLens Back to search
2022•C&EN Global EnterpriseRequires access

Seqirus opens lab for sa-mRNA research

Michael McCoy

Open publisher page 0 citations

Abstract

Seqirus, part of the flu vaccine firm CSL, has opened a facility in Waltham, Massachusetts, focused on self-amplifying messenger RNA (sa-mRNA), which Seqirus calls the next generation of mRNA technology. mRNA vaccines give instructions to cells to make a protein, stimulating an immune response. sa-mRNA also instructs the body to replicate the mRNA, amplifying the amount of protein made. Seqirus says the result could be vaccines for the flu and other diseases that are effective at smaller doses and have fewer side effects.

About this research paper

What this paper is about

Seqirus, part of the flu vaccine firm CSL, has opened a facility in Waltham, Massachusetts, focused on self-amplifying messenger RNA (sa-mRNA), which Seqirus calls the next generation of mRNA technology. mRNA vaccines give instructions to cells to make a protein, stimulating an immune response. sa-mRNA also instructs the body to replicate the mRNA, amplifying the amount of protein made. Seqirus says the result could be vaccines for the flu and other diseases that are effective at smaller doses and have fewer side effects.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Seqirus, part of the flu vaccine firm CSL, has opened a facility in Waltham, Massachusetts, focused on self-amplifying messenger RNA (sa-mRNA), which Seqirus calls the next generation of mRNA technology. mRNA vaccines give instructions to cells to make a protein, stimulating an immune response. sa-mRNA also instructs the body to replicate the mRNA, amplifying the amount of protein made. Seqirus says the result could be vaccines for the flu and other diseases that are effective at smaller doses and have fewer side effects.

Key concepts: Messenger RNA, RNA, Replicate, Immune system, Biology, Virology, Cell biology, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Seqirus opens lab for sa-mRNA research — Research Paper | ScholarLens